

IN THE SPECIFICATION

Please replace the title of the application, shown at the top of page 1, with the following rewritten title:

Changed in title
-- Treatment of ~~T-Cell Mediated Autoimmune Disorders~~ Diabetes with Anti-gp39 Antibodies
--

Please replace the paragraph beginning at page 6, line 15, with the following rewritten paragraph:

B₁
-- Methodologies for producing monoclonal antibodies directed against gp39, including human gp39 and mouse gp39, and suitable monoclonal antibodies for use in the methods of the invention, are described in PCT Patent Application No. WO 95/06666 entitled "Anti-gp39 Antibodies and Uses Therefor", the teachings of which are incorporated by reference. Particularly preferred anti-human gp39 antibodies of the invention are mAbs 24-31 and 89-76, produced respectively by hybridomas 24-31 and 89-76. The 89-76 and 24-31 hybridomas, producing the 89-76 and 24-31 antibodies, respectively, were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection, ~~Parklawn Drive, Rockville, Md.,~~ 10801 University Boulevard, Manassas, VA 20110-2209, on September 2, 1994. The 89-76 hybridoma was assigned ATCC Accession Number HB 11713 and the 24-31 hybridoma was assigned ATCC Accession Number HB 11712. --

Please replace the abstract on page 15, with the following rewritten abstract:

B₂
Method for the treatment of ~~multiple sclerosis and other T cell mediated autoimmune disorders~~ diabetes is described. The method involves administering to a subject in need of such treatment a therapeutically effective amount of ~~an~~ a gp39 antagonist ~~of a receptor on a surface of a T cell which mediates contact dependent helper effector functions~~, for example, an anti-gp39 antibody.